Brief Article
Copyright ©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 14, 2011; 17(30): 3518-3525
Published online Aug 14, 2011. doi: 10.3748/wjg.v17.i30.3518
Table 3 Prevalence of cancer screening n (%)
Controls (n = 2842)Non-gastric cancer relatives (n = 454)Gastric cancer relatives (n = 261)
Stomach cancer screening (within 2 yr)
Crude rate894 (32.3)162 (37.2)100 (39.2)
Adjusted rate (%, 95% CI)232.2 (30.5, 34.0)35.2 (30.8, 39.8)38.1 (32.3, 44.2)
Crude OR (95% CI)1 (referent)1.16 (0.89, 1.50)1.47 (1.08, 2.00)a
Adjusted OR (95% CI)11 (referent)1.08 (0.83, 1.41)1.43 (1.05, 1.95)a
Breast cancer screening (within 2 yr)
Crude rate456 (29.6)102 (40.8)61 (40.9)
Adjusted rate (%, 95% CI)228.9 (26.7, 31.4)36.5 (30.7, 42.8)38.5 (31.0, 46.7)
Crude OR (95% CI)1 (referent)1.68 (1.21, 2.33)a1.53 (1.05, 2.23)a
Adjusted OR (95% CI)11 (referent)1.42 (1.02, 2.00)a1.40 (0.95, 2.08)
Cervical cancer screening (within 2 yr)
Crude rate596 (39.9)133 (53.9)71 (47.7)
Adjusted rate (%, 95% CI)239.1 (36.5, 41.8)47.3 (40.7, 54.1)43.2 (35.1, 51.7)
Crude OR (95% CI)1 (referent)1.90 (1.35, 2.68)a1.33 (0.90, 1.97)
Adjusted OR (95% CI)11 (referent)1.51 (1.04, 2.20)a1.14 (0.76, 1.71)
Colon cancer screening (within 5 yr)
Crude rate309 (17.5)55 (23.6)33 (21.4)
Adjusted rate (%, 95% CI)217.2 (15.4, 19.0)22.6 (17.7, 28.5)20.2 (14.6, 27.3)
Crude OR (95% CI)1 (referent)1.17 (0.78, 1.74)1.48 (0.85, 2.56)
Adjusted OR (95% CI)11 (referent)1.10 (0.73, 1.67)1.41 (0.83, 2.41)